The EPO granted patent EP3600036A1 to Medtronic MiniMed, Inc. on March 25, 2026, covering patient-specific glucose prediction systems and methods for diabetes management. The patent application includes multiple inventors and covers designated European states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). The IPC classification is A61B 5/145.

This is a patent publication rather than a regulatory or compliance requirement. No action is required from healthcare providers, device manufacturers, or patients. Competitors in the diabetes management space should review this patent to assess potential IP implications for their own product development. There are no compliance deadlines, filing requirements, or penalties associated with this document.